Mark53 Studies

Led by Univ. Prof. Dr. Daniela Kandioler, between 1999 and 2013 the impact of the TP53 gene status on the response to chemotherapy or radiation therapy was investigated in clinical biomarker studies on more than 1,000 cancer patients at the Medical University of Vienna.

The study results, as well as ongoing biomarker studies with all study details, are to be found on the website of the research group p53research at: